# Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis

> **NCT01814475** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Trapianto di Midollo Osseo** · enrollment: 62 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** A: Fludarabine + Busulphan
- **DRUG:** B: Fludarabine + Thiotepa

## Key facts

- **NCT ID:** NCT01814475
- **Lead sponsor:** Gruppo Italiano Trapianto di Midollo Osseo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814475, "Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01814475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*